BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-274@pharmaconomics
DTSTAMP:20260707T022054Z
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260603
SUMMARY:NUVL Phase 1 — zidesamtinib (estimated date)
DESCRIPTION:Phase 1 trial results for zidesamtinib in ROS1-positive solid tumors are due ~ Jun 2\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1861560/000186156026000020/nuvl-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/274
URL:https://www.pharmaconomics.com/e/274
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:NUVL catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR